A Randomized Multicenter Trial of Neoadjuvant Taxotere (T) and Adriamycin/Cytoxan (Ac): A Validation.

Trial Profile

A Randomized Multicenter Trial of Neoadjuvant Taxotere (T) and Adriamycin/Cytoxan (Ac): A Validation.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2016

At a glance

  • Drugs Docetaxel (Primary) ; Cyclophosphamide; Doxorubicin
  • Indications Breast cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms TACAC
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Aug 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Oct 2016.
    • 23 Aug 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top